Compare American Financial Group Inc (AFG) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? American Financial Group Inc trades at $144.65 (market cap $11.93B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: American Financial Group Inc is the larger of the two by market cap, and American Financial Group Inc pays a 2.45% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| AFG | BIO | |
|---|---|---|
Market Cap | $11.93B | $9.39B |
Sector | Financials | Health |
52-Week High | $148.71 | $356.25 |
52-Week Low | $124.18 | $241.71 |
Enterprise Value | $12.31B | $9.14B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Financial Group (AFG) trades at $145.59, down 0.78% on the day, with strong technical momentum indicated by bullish moving averages. The company reported solid Q2 2026 earnings of $2.82 per share, beating estimates by 21.6%, driven by record property and casualty operating income. Recent news highlights strong underwriting margins and premium growth, while institutional activity shows mixed positioning with some funds increasing stakes and others reducing holdings.
AFG presents a compelling investment case with a reasonable P/E of 12.73 and strong ROE of 20.41%, supported by consistent dividend payments. The consensus price target of $159.00 suggests 9.2% upside potential. Key risks include competitive pressures in insurance markets and potential margin compression. Analyst sentiment is cautiously optimistic with 41% buy ratings, though the majority maintain hold recommendations awaiting clearer growth catalysts.
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
